Se nyt newsfeed for de største c20 selskaber her – til højre på ØU Flash News
Novo Nordisk: Buy The Diabetes Treatment Leader On Recent Weakness
Novo Nordisk is the worldwide leader in diabetes drugs.
Their earnings growth was revised down in the last quarter, causing a ~28% sell-off.
This represents an attractive entry point for this well-run company.